The effect of anakinra on paclitaxel-induced peripheral neuropathic pain in rats

ArticleAçık Erişim

Özet

Objective: Paclitaxel is used in the treatment of cancer, and it may cause interleukin-1 beta (IL-1β)-related peripheral neuropathic pain. While our primary aim was to investigate the analgesic efficacy of an IL-1β antagonist, a secondary outcome was to assess whether a correlation exists between analgesic effects and antioxidant activity. Methods: A total of 24 albino Wistar male rats were divided into the following groups: paclitaxel-control, paclitaxel+50 mg kg−1 anakinra, paclitaxel+100 mg kg−1 anakinra and healthy group (HG). After the normal paw pain threshold in all animal groups was measured using a Basile algesimeter, a single dose of 2 mg kg−1 paclitaxel was intraperitoneally administered on the 1st, 3rd, 5th and 7th days. Anakinra was intraperitoneally administered following the final paclitaxel administration. The paw pain thresholds in the groups were measured before and seven days after paclitaxel administration and at the 1st and 3rd hours after anakinra administration. After the third hour of measurement, the rats were killed with high doses of ketamine, and the paw tissues were removed. Malondialdehyde, myeloperoxidase and total glutathione levels were measured in claw tissues, and IL-1β gene expression was determined. The biochemical results were compared with the results of the HG; in the meanwhile the claw pain threshold results were compared with the results obtained after the last paclitaxel and the results obtained from the 1st and 3rd hours after the anakinra application. Results: The claw paw pain threshold of the rats decreased one and three hours after anakinra administration. Further, 100 mg kg−1 anakinra had greater analgesic activity than 50 mg kg−1 anakinra. A correlation was found between the antioxidant and analgesic activities of 100 mg kg−1 anakinra. Conclusion: Anakinra may be useful to reduce paclitaxel-induced neuropathic pain; further, 100 mg kg−1 anakinra may have greater analgesic and antioxidant activities. © 2016 by Turkish Anaesthesiology and Intensive Care Society.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/14678Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.5152/tjar.2016.02212Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorKuyrukluyıldız, Ufuk
dc.contributor.authorKüpeli, İlke
dc.contributor.authorBedir, Zehra
dc.contributor.authorÖzmen, Özgür
dc.contributor.authorOnk, Didem
dc.contributor.authorSüleyman, Bahadır
dc.contributor.authorMammadov, Renad
dc.contributor.authorSüleyman, Halis
dc.date.accessioned2026-10-18T20:29:28.472787797Z
dc.date.available2026-10-18T20:29:28.472787797Z
dc.date.issued2016
dc.description.abstractObjective: Paclitaxel is used in the treatment of cancer, and it may cause interleukin-1 beta (IL-1β)-related peripheral neuropathic pain. While our primary aim was to investigate the analgesic efficacy of an IL-1β antagonist, a secondary outcome was to assess whether a correlation exists between analgesic effects and antioxidant activity. Methods: A total of 24 albino Wistar male rats were divided into the following groups: paclitaxel-control, paclitaxel+50 mg kg−1 anakinra, paclitaxel+100 mg kg−1 anakinra and healthy group (HG). After the normal paw pain threshold in all animal groups was measured using a Basile algesimeter, a single dose of 2 mg kg−1 paclitaxel was intraperitoneally administered on the 1st, 3rd, 5th and 7th days. Anakinra was intraperitoneally administered following the final paclitaxel administration. The paw pain thresholds in the groups were measured before and seven days after paclitaxel administration and at the 1st and 3rd hours after anakinra administration. After the third hour of measurement, the rats were killed with high doses of ketamine, and the paw tissues were removed. Malondialdehyde, myeloperoxidase and total glutathione levels were measured in claw tissues, and IL-1β gene expression was determined. The biochemical results were compared with the results of the HG; in the meanwhile the claw pain threshold results were compared with the results obtained after the last paclitaxel and the results obtained from the 1st and 3rd hours after the anakinra application. Results: The claw paw pain threshold of the rats decreased one and three hours after anakinra administration. Further, 100 mg kg−1 anakinra had greater analgesic activity than 50 mg kg−1 anakinra. A correlation was found between the antioxidant and analgesic activities of 100 mg kg−1 anakinra. Conclusion: Anakinra may be useful to reduce paclitaxel-induced neuropathic pain; further, 100 mg kg−1 anakinra may have greater analgesic and antioxidant activities. © 2016 by Turkish Anaesthesiology and Intensive Care Society.
dc.identifier.doi10.5152/tjar.2016.02212
dc.identifier.eissn2149-276X
dc.identifier.endpage294
dc.identifier.issn1304-0871
dc.identifier.issue6
dc.identifier.pmcidPMC5207416
dc.identifier.pmid28058139
dc.identifier.scopus2-s2.0-85008157792
dc.identifier.startpage287
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/14678
dc.identifier.volume44
dc.identifier.wosWOS:000393325300005
dc.language.isoen
dc.publisherAVES Ibrahim Kara
dc.relation.ispartofTurk Anesteziyoloji ve Reanimasyon Dernegi Dergisi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAnakinra
dc.subjectOxidative stress
dc.subjectPaclitaxel
dc.subjectPain
dc.subjectPeripheral neuropathy
dc.titleThe effect of anakinra on paclitaxel-induced peripheral neuropathic pain in rats
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus21
rdl.citation.wos22
rdl.departmentDepartment of Anesthesiology and Reanimation, Erzincan University School of Medicine, Erzincan, Turkey. | Department of Pharmacology, Erzincan University School of Medicine, Erzincan, Turkey.
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexEmerging Sources Citation Index (ESCI)